
Opinion|Videos|July 17, 2024
SEQUOIA Arm D Study: Zanubrutinib plus Venetoclax in Treatment-Naive CLL/SLL with del(17p) and/or TP53 Mutations
Author(s)Mazyar Shadman, MD, MPH
A blood cancer specialist discusses the latest data from the SEQUOIA Arm D trial investigating zanubrutinib plus venetoclax in treatment-naïve patients with CLL and del(17p) and/or TP53 mutations.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Please briefly discuss the latest results from the SEQUOIA Arm D trial, evaluating zanubrutinib plus venetoclax in treatment-naïve patients with CLL and del(17p) and/or TP53 mutations.
- How does the efficacy of zanubrutinib + venetoclax compare to SOCs in high-risk patients with del(17p) and/or TP53 mutations in CLL/SLL?
- How does the efficacy of zanubrutinib + venetoclax compare to SOCs in high-risk patients with del(17p) and/or TP53 mutations in CLL/SLL?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
3
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
4
Neoadjuvant Pembrolizumab Achieves High pCR Rates in Desmoplastic Melanoma
5



















